Department of Pathology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China.
Chin J Cancer Res. 2012 Jun;24(2):103-8. doi: 10.1007/s11670-012-0103-1.
To examine the expressions of osteopontin (OPN), (α) (ν) (β) (3) and Pim-1 in non-small cell lung cancer (NSCLC), and investigate their potential pathogenic roles in the development of NSCLC.
Immunohistochemistry was used to examine the expressions of OPN, (α) (ν) (β) (3) and Pim-1 in cohort (136 cases) of NSCLC samples and their adjacent normal lung tissue specimens. Statistical analysis was performed to evaluate the relationships among expressions of OPN, (α) (ν) (β) (3) and Pim-1 and their associations with patients clinico- pathological parameters.
The expressions of OPN and Pim-1 were predominantly observed in cytoplasm. The expression of (α) (ν) (β) (3) was mostly detected in cytoplasm and/or membrane. In NSCLC samples, the positive rates of OPN, (α) (ν) (β) (3) and Pim-1 expressions were 68.4% (93/136), 77.2% (105/136) and 57.4% (78/136), respectively. In normal lung tissues, in contrast, the positive rates of OPN, (α) (ν) (β) (3) and Pim-1 were 24.0% (12/50), 26.0% (13/50) and 16.0% (8/50), respectively. There were significant differences of the positive expression rates of OPN, (α) (ν) (β) (3) and Pim-1 between NSCLCs samples and normal lung tissues (P<0.01). In addition, the positive expression of OPN, (α) (ν) (β) (3) and Pim-1 in NSCLCs samples was significantly associated with increased pathological grade, lymph node metastasis and advanced clinical stage (P<0.01), and they were independent of other clinicopathological parameters (P>0.05). Furthermore, a significantly positive correlation between the expression of OPN and (α) (ν) (β) (3) (r=0.38, P<0.01), OPN and Pim-1 (r=0.37, P<0.01), or (α) (ν) (β) (3) and Pim-1 (r=0.20, P<0.05) was evaluated in our NSCLC cohort.
OPN, (α) (ν) (β) (3) and Pim-1 proteins are frequently overexpressed in NSCLC, and they may play important roles in the development and/or progression of NSCLC.
检测骨桥蛋白（OPN）、（α）（ν）（β）（3）和 Pim-1 在非小细胞肺癌（NSCLC）中的表达，并探讨它们在 NSCLC 发展中的潜在致病作用。
采用免疫组织化学法检测 NSCLC 队列（136 例）样本及其相邻正常肺组织标本中 OPN、（α）（ν）（β）（3）和 Pim-1 的表达。统计学分析评估 OPN、（α）（ν）（β）（3）和 Pim-1 的表达之间的关系及其与患者临床病理参数的关联。
OPN 和 Pim-1 的表达主要位于细胞质中。（α）（ν）（β）（3）的表达主要在细胞质和/或膜中检测到。在 NSCLC 样本中，OPN、（α）（ν）（β）（3）和 Pim-1 的阳性表达率分别为 68.4%（93/136）、77.2%（105/136）和 57.4%（78/136）。相比之下，在正常肺组织中，OPN、（α）（ν）（β）（3）和 Pim-1 的阳性表达率分别为 24.0%（12/50）、26.0%（13/50）和 16.0%（8/50）。NSCLCs 样本和正常肺组织中 OPN、（α）（ν）（β）（3）和 Pim-1 的阳性表达率存在显著差异（P<0.01）。此外，OPN、（α）（ν）（β）（3）和 Pim-1 在 NSCLCs 样本中的阳性表达与病理分级升高、淋巴结转移和临床晚期显著相关（P<0.01），并且与其他临床病理参数无关（P>0.05）。此外，在我们的 NSCLC 队列中，OPN 与（α）（ν）（β）（3）（r=0.38，P<0.01）、OPN 与 Pim-1（r=0.37，P<0.01）或（α）（ν）（β）（3）与 Pim-1（r=0.20，P<0.05）之间存在显著正相关。
OPN、（α）（ν）（β）（3）和 Pim-1 蛋白在 NSCLC 中常过度表达，它们可能在 NSCLC 的发展和/或进展中发挥重要作用。
